Curi RMB Capital LLC Has $22.45 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Curi RMB Capital LLC lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 1.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 114,911 shares of the company’s stock after selling 1,977 shares during the quarter. Curi RMB Capital LLC’s holdings in Zoetis were worth $22,451,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Prevail Innovative Wealth Advisors LLC boosted its stake in Zoetis by 24.5% in the first quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock valued at $3,211,000 after buying an additional 3,738 shares in the last quarter. M&G Plc bought a new stake in shares of Zoetis during the 1st quarter valued at approximately $19,819,000. Cetera Investment Advisers increased its position in Zoetis by 275.2% during the 1st quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock worth $16,259,000 after purchasing an additional 70,476 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Zoetis by 49.6% in the 1st quarter. Acadian Asset Management LLC now owns 25,051 shares of the company’s stock valued at $4,235,000 after purchasing an additional 8,302 shares during the last quarter. Finally, Soltis Investment Advisors LLC acquired a new stake in Zoetis in the first quarter valued at approximately $688,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 1.9 %

ZTS stock opened at $177.28 on Thursday. The stock has a market cap of $79.98 billion, a P/E ratio of 33.32, a P/E/G ratio of 2.67 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock’s fifty day simple moving average is $187.61 and its two-hundred day simple moving average is $180.02. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.36 EPS. Analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 32.52%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Stifel Nicolaus increased their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research upped their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Piper Sandler raised their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.